3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
68
Stomach Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Inflammatory Breast Neoplasms
3
Breast Neoplasms, Male
3
Solid Tumor
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
HER2-positive Breast Cancer
2
Colonic Neoplasms
2
Carcinoma, Ductal, Breast
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Neoplasms, Unknown Primary
1
Metastatic HER2-Positive Breast Cancer
1
Lung Neoplasms
1
Her2-Positive Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Elderly Metastatic Breast Cancer Population
1
Colorectal Neoplasms
1
Carcinoma, Neuroendocrine
1
Biliary Tract Neoplasms
1
Interventions
pertuzumab
1
pazopanib
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Risk Assessment
1
Radiotherapy
1
Injections, Subcutaneous
1
Focus Groups
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Patient Preference
×
pertuzumab
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts